CJC-1295 DAC
Educational resource. Not medical advice. No dosing or instructions.
Safety grade
5/10
Moderate
Also known as
cjc 1295 daccjc daccjc-1295 daccjc-1295-daccjc1295cjc1295 daccjc1295dac
AA sequence
Not available yet.
No overview has been added yet.
Why people are interested in this peptide and how it is commonly discussed in real-world wellness, rehabilitation, and athletic communities.
Why people are interested
- Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.
- general recovery and resilience interest (anecdotal)
- common biohacker curiosity due to community reports
- interest in mechanisms suggested by early evidence
- used in goal-based stacking discussions (anecdotal)
- exploration in wellness communities despite evidence limits
CJC-1295 DAC is a long-acting GHRH analog discussed for growth-hormone axis effects. Endocrine manipulation carries real risks, and long-acting exposure can amplify side effects and monitoring needs.
Common reasons people consider it
- growth-hormone axis interest (variable; claims often exceed evidence)
- sometimes discussed for body composition and recovery themes (anecdotal heavy)
- long-acting design is a major differentiator (also increases risk if misused)
Most commonly reported downsides
- water retention or swelling
- headache
- flushing at the site or generalized warmth
- sleep disruption in some users
Rare but important symptoms to watch for
These are uncommon, but if they occur, stop and seek medical care.
- severe swelling, shortness of breath, or chest pain
- severe blood sugar changes symptoms (confusion, fainting) in susceptible users
- severe allergic reaction symptoms (hives, facial swelling, trouble breathing)
Who should be cautious
- people with diabetes or unstable blood sugar control
- people with cancer history or active malignancy concerns (growth signaling context)
- people with significant cardiovascular disease or uncontrolled blood pressure
- pregnant or breastfeeding individuals
- adolescents (developmental endocrine risk plus inappropriate use context)
Interactions summarize known or plausible ways this peptide may intersect with medications, supplements, or physiologic states. Use this as a risk-awareness map: what to ask about, what to watch for, and what deserves a clinician conversation.
Medication classes
Supplement classes
None
Other peptides
None
Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.
No curated human clinical sources have been added yet.
Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.
Pep-Talk is informational only and not medical advice. We make no warranties and are not liable for actions you take. You are responsible for your decisions and outcomes.
Community notes
Educational discussion only. No dosing, protocols, schedules, or instructions. Submissions are moderated before appearing.
Loading…
Submit a note